M-136

Methotrexate solution

Name: Methotrexate solution
Brand: CERILLIAN
Price: 69.67 USD

1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant^®

Slide 1 of 1

Select a Size

1 ML

$69.67

List Price$92.90Save 25%

Check Cart for Availability

Need it sooner? View alternative products.

Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):

C₂₀H₂₂N₈O₅

CAS Number:

59-05-2

Molecular Weight:

454.44

NACRES:

NA.24

PubChem Substance ID:

329817872

UNSPSC Code:

41116107

MDL number:

MFCD00064369

Key Documents

View All Documentation

Product Name

Methotrexate solution, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant^®

form

liquid

feature

Snap-N-Spike^®/Snap-N-Shoot^®

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)

SMILES string

O=C(C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)NC(C(O)=O)CCC(O)=O

InChI key

FBOZXECLQNJBKD-UHFFFAOYSA-N

grade

certified reference material

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant^®

concentration

1.0 mg/mL in methanol with 0.1N NaOH

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

single component solution

storage temp.

−20°C

Quality Level

300

Related Categories

Certified Reference Materials

Controlled Substances & Illicit Drug Standards

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	PHR1396	1414003	M1000000
Supelco M-136 Methotrexate solution	Supelco PHR1396 Methotrexate	USP 1414003 Methotrexate	M1000000 Methotrexate
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)
technique(s) gas chromatography (GC): suitable, liquid chromatography (LC): suitable	technique(s) HPLC: suitable, gas chromatography (GC): suitable	technique(s) -	technique(s) -
form liquid	form -	form -	form -
Quality Level 300	Quality Level 300	Quality Level -	Quality Level -
grade certified reference material	grade certified reference material, pharmaceutical secondary standard	grade pharmaceutical primary standard	grade pharmaceutical primary standard
storage temp. −20°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. -

General description

A Certified Spiking Solution^® for use in therapeutic drug monitoring (TDM) analyses by HPLC or LC/MS. Used in the treatment of cancer and autoimmune diseases, methotrexate is an antimetabolite and antifolate drug monitored by clinical labs to ensure patients remain within the drug′s therapeutic range. The Snap-N-Spike^® format allows laboratories to eliminate weighing operations of hazardous substances such as methotrexate, significantly reducing occupational exposure hazards related to handling of acutely toxic powders, and provides the ability to spike into their matrix of choice just before use.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.

Description

Pricing

M-153

Methotrexate-D₃ solution, 100 μg/mL in methanol with 0.01N NaOH, ampule of 1 mL, certified reference material, Cerilliant^®

F-087

Folic acid solution, 1 mg/mL in methanol with 0.1N NaOH, certified reference material, ampule of 1 mL, Cerilliant^®

F-088

Folic acid-¹³C₅,¹⁵N solution, 100 μg/mL (Methanol with 0.1 N NaOH), certified reference material, ampule of 1 mL, Cerilliant^®

pictograms

GHS02,GHS06,GHS08,GHS05

signalword

Danger

hcodes

H225,H290,H301 + H311 + H331,H370

pcodes

P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Met. Corr. 1 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

51.8 °F - closed cup

flash_point_c

11 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.

Joshua F Baker et al.

Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)

To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th

Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.

J Westra et al.

Clinical and experimental immunology, 178(1), 40-47 (2014-06-04)

Rituximab (RTX) treatment in rheumatoid arthritis (RA) patients severely hampers humoral response after influenza vaccination as determined by haemagglutination inhibition assay (HI). It is not known whether HI reflects both immunoglobulin (Ig)M and IgG (subclass) influenza response, and whether IgM

Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.

Daniel H Solomon et al.

The American journal of medicine, 126(8), 730-730 (2013-07-28)

Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). Subjects with rheumatoid

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Josef S Smolen et al.

Lancet (London, England), 383(9914), 321-332 (2013-10-31)

Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early

Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials.

Richard Conway et al.

Arthritis & rheumatology (Hoboken, N.J.), 66(4), 803-812 (2014-04-24)

Methotrexate has shown efficacy for the treatment of several diseases, especially rheumatoid arthritis (RA). Methotrexate has also been implicated as a causative agent in interstitial lung disease. Patients with RA may develop pulmonary manifestations of their disease and are at

View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service